CASI Pharmaceuticals (CASI) Short Interest Ratio & Short Volume → Biden to Drop BOMBSHELL June 13th? (From Paradigm Press) (Ad) Free CASI Stock Alerts $3.39 +0.22 (+6.94%) (As of 05/15/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability CASI Pharmaceuticals Short Interest DataCurrent Short Volume46,300 sharesPrevious Short Volume62,500 sharesChange Vs. Previous Month-25.92%Dollar Volume Sold Short$106,490.00Short Interest Ratio / Days to Cover0.2Last Record DateApril 30, 2024Outstanding Shares13,400,000 sharesFloat Size6,330,000 sharesShort Percent of Float0.73%Today's Trading Volume60,862 sharesAverage Trading Volume145,226 sharesToday's Volume Vs. Average42% Short Selling CASI Pharmaceuticals ? Sign up to receive the latest short interest report for CASI Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatCASI Short Interest Over TimeCASI Days to Cover Over TimeCASI Percentage of Float Shorted Over Time Ad Monetary GoldDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.This means you must act NOW before it's too late. CASI Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/202446,300 shares $106,490.00 -25.9%0.7%0.2 $2.30 4/15/202462,500 shares $153,125.00 -24.0%1.0%0.3 $2.45 3/31/202482,200 shares $296,742.00 -35.4%1.3%0.4 $3.61 3/15/2024127,300 shares $404,814.00 +204.6%2.2%0.7 $3.18 2/29/202441,800 shares $233,662.00 -21.3%0.7%0.2 $5.59 2/15/202453,100 shares $323,379.00 +0.8%0.9%1.1 $6.09 Get the Latest News and Ratings for CASI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for CASI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/31/202452,700 shares $361,522.00 +10.0%0.9%1 $6.86 1/15/202447,900 shares $291,232.00 +74.8%0.8%0.9 $6.08 12/31/202327,400 shares $196,184.00 -18.7%0.5%0.5 $7.16 12/15/202333,700 shares $206,581.00 -58.4%0.6%0.6 $6.13 11/30/202381,000 shares $452,790.00 -46.4%1.4%1.9 $5.59 11/15/2023151,200 shares $657,720.00 -33.0%2.5%4.9 $4.35 10/31/2023225,700 shares $911,828.00 +0.6%3.4%9 $4.04 10/15/2023224,400 shares $587,928.00 -2.6%3.4%12 $2.62 9/30/2023230,400 shares $589,824.00 -1.5%3.5%15.8 $2.56 9/15/2023233,900 shares $493,529.00 -1.6%3.5%22.1 $2.11 8/31/2023237,600 shares $548,856.00 -1.4%3.6%9.1 $2.31 8/15/2023241,000 shares $535,020.00 +2.4%3.6%8.1 $2.22 7/31/2023235,300 shares $571,779.00 -3.6%3.5%7.7 $2.43 7/15/2023244,100 shares $646,865.00 -2.6%3.7%8.2 $2.65 6/30/2023250,700 shares $624,243.00 -7.4%3.8%6.9 $2.49 6/15/2023270,800 shares $557,848.00 +12.6%4.1%5.2 $2.06 5/31/2023240,500 shares $678,210.00 -5.1%3.4%6.5 $2.82 5/15/2023253,300 shares $640,646.36 -0.7%3.6%7.3 $2.53 4/30/2023255,200 shares $730,382.40 -5.0%3.6%7.3 $2.86 4/15/2023268,700 shares $964,633.00 +6.5%3.6%7.1 $3.59 3/31/2023252,200 shares $585,104.00 +3.4%2.7%6.4 $2.32 3/15/2023244,000 shares $417,240.00 -6.1%2.6%9.1 $1.71 2/28/2023259,700 shares $501,221.00 -1.7%2.8%8.3 $1.93 2/15/2023264,300 shares $509,781.84 +0.9%2.2%8 $1.93 1/31/2023262,000 shares $534,480.00 -5.7%2.0%7.8 $2.04 1/15/2023277,800 shares $548,655.00 -5.9%2.1%8.2 $1.98 12/30/2022295,200 shares $528,408.00 +44.1%2.3%8.7 $1.79 12/15/2022204,900 shares $370,869.00 +77.6%1.6%5.5 $1.81 11/30/2022115,400 shares $229,646.00 +27.4%0.9%2.6 $1.99 11/15/202290,600 shares $176,670.00 -13.6%0.7%1.6 $1.95 10/31/2022104,900 shares $206,653.00 -9.6%1.0%0.6 $1.97 10/15/2022116,000 shares $257,520.00 +26.2%1.1%0.6 $2.22 9/30/202291,900 shares $238,940.00 -41.5%0.9%0.4 $2.60 9/15/2022157,200 shares $664,956.00 +28.9%1.5%0.7 $4.23Biden to Drop BOMBSHELL June 13th? (Ad)Biden’s days are numbered! According to a former CIA and Pentagon insider… He’s about to drop out of the presidential race on June 13th!Click here now to see his shocking evidence. CASI Short Interest - Frequently Asked Questions What is CASI Pharmaceuticals' current short interest? Short interest is the volume of CASI Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 30th, traders have sold 46,300 shares of CASI short. 0.73% of CASI Pharmaceuticals' shares are currently sold short. Learn More on CASI Pharmaceuticals' current short interest. Which institutional investors are shorting CASI Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of CASI Pharmaceuticals: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for CASI Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.73% of CASI Pharmaceuticals' floating shares are currently sold short. Is CASI Pharmaceuticals' short interest increasing or decreasing? CASI Pharmaceuticals saw a decline in short interest in April. As of April 30th, there was short interest totaling 46,300 shares, a decline of 25.9% from the previous total of 62,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is CASI Pharmaceuticals' float size? CASI Pharmaceuticals currently has issued a total of 13,400,000 shares. Some of CASI Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. CASI Pharmaceuticals currently has a public float of 6,330,000 shares. How does CASI Pharmaceuticals' short interest compare to its competitors? 0.73% of CASI Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to CASI Pharmaceuticals: Eyenovia, Inc. (12.11%), VYNE Therapeutics Inc. (0.68%), Gain Therapeutics, Inc. (1.02%), Unicycive Therapeutics, Inc. (2.13%), HCW Biologics Inc. (0.05%), Ocuphire Pharma, Inc. (4.71%), Xilio Therapeutics, Inc. (5.24%), Lexaria Bioscience Corp. (2.29%), NextCure, Inc. (0.53%), Cara Therapeutics, Inc. (5.62%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short CASI Pharmaceuticals stock? Short selling CASI is an investing strategy that aims to generate trading profit from CASI Pharmaceuticals as its price is falling. CASI shares are trading up $0.22 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against CASI Pharmaceuticals? A short squeeze for CASI Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CASI, which in turn drives the price of the stock up even further. How often is CASI Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CASI, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: Eyenovia Short Squeeze VYNE Therapeutics Short Squeeze Gain Therapeutics Short Squeeze Unicycive Therapeutics Short Squeeze HCW Biologics Short Squeeze Ocuphire Pharma Short Squeeze Xilio Therapeutics Short Squeeze Lexaria Bioscience Short Squeeze NextCure Short Squeeze Cara Therapeutics Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CASI) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTop 5 AI Stocks to Buy for 2024Market Moving TrendsThis unknown company solves the biggest issue with AIManward PressTrump’s “Tax Free” Retirement Strategy Gold Safe Exchange